Filing Details

Accession Number:
0001209191-21-052248
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-08-18 17:02:02
Reporting Period:
2021-08-17
Accepted Time:
2021-08-18 17:02:02
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1699382 Pmv Pharmaceuticals Inc. PMVP Pharmaceutical Preparations (2834) 463218129
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1825192 Deepika Jalota C/O Pmv Pharmaceuticals, Inc.
8 Clarke Drive, Suite 3
Cranbury NJ 08512
Svp, Regulatory Affairs And Qa No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-08-17 2,896 $3.53 2,896 No 4 M Direct
Common Stock Disposition 2021-08-17 2,896 $33.78 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock option (right to buy) Disposition 2021-08-17 2,896 $0.00 2,896 $3.53
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
87,320 2029-08-20 No 4 M Direct
Footnotes
  1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 29, 2020.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.50 to $34.125, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
  3. One-fourth of the shares subject to the option vested on June 10, 2020 and one forty-eighth of the shares subject to the option shall vest each month thereafter.